Scarica l'app Stockscreener
2.13
3.90%
0.08
Dopo l'orario di chiusura:
2.14
0.01
+0.47%
Panoramica
Notizia
Cronologia dei prezzi
Financials
Perché ALZN Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$2.05
Aprire:
$2.06
Volume 24 ore:
43,975
Relative Volume:
0.44
Capitalizzazione di mercato:
$8.10M
Reddito:
-
Utile/perdita netta:
$-6.24M
Rapporto P/E:
-0.3814
EPS:
-5.5853
Flusso di cassa netto:
$-8.09M
1 W Prestazione:
+10.94%
1M Prestazione:
-5.33%
6M Prestazione:
-27.55%
1 anno Prestazione:
-81.36%
Intervallo 1D:
$2.00
$2.135
Intervallo di 1 settimana:
$1.69
$2.135
Portata 52W:
$1.69
$11.70
Alzamend Neuro Inc Stock (ALZN) Company Profile
Nome
Alzamend Neuro Inc
Settore
Industria
Telefono
844-722-6333
Indirizzo
3500 LENOX RD. NE, ATLANTA
Confronta ALZN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ALZN
Alzamend Neuro Inc
|
2.13 | 7.79M | 0 | -6.24M | -8.09M | -5.5853 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Alzamend Neuro Inc Stock (ALZN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2021-10-01 | Iniziato | Ascendiant Capital Markets | Buy |
Alzamend Neuro Inc Borsa (ALZN) Ultime notizie
Momentum Shift: Will Alzamend Neuro Inc stock attract ESG investorsEarnings Performance Report & Stepwise Trade Signal Implementation - moha.gov.vn
Ascendiant Sticks to Their Buy Rating for Alzamend Neuro (ALZN) - The Globe and Mail
Ascendiant Capital Maintains Alzamend Neuro (ALZN) Buy Recommendation - Nasdaq
ALZN: Ascendiant Capital Lowers Price Target, Maintains Buy Rati - GuruFocus
Decliners Report: Why Alzamend Neuro Inc. stock is recommended by analystsQuarterly Market Review & Detailed Earnings Play Strategies - Улправда
Will Alzamend Neuro Inc. stock deliver long term returnsWeekly Profit Analysis & Consistent Profit Trade Alerts - Улправда
Is Alzamend Neuro Inc. stock attractive for ETFs2025 Support & Resistance & Community Verified Trade Signals - Улправда
Can Alzamend Neuro Inc. stock maintain growth trajectoryWeekly Trade Analysis & Risk Managed Trade Strategies - DonanımHaber
Why Alzamend Neuro Inc. stock is recommended by analystsQuarterly Growth Report & Verified Momentum Watchlists - Улправда
Can Alzamend Neuro Inc. stock sustain market leadershipJuly 2025 Chart Watch & Consistent Return Investment Signals - Улправда
Alzamend Neuro, Inc. SEC 10-Q Report - TradingView
Is Alzamend Neuro Inc stock attractive for passive investorsWeekly Investment Summary & Weekly Top Gainers Alerts - BỘ NỘI VỤ
Why Alzamend Neuro Inc. stock remains undervaluedJuly 2025 Analyst Calls & High Accuracy Trade Alerts - Newser
Alzamend Neuro (ALZN) Stock Analysis Report | Financials & Insights - Benzinga
Alzamend Neuro Mourns Loss of Director Andrew Woo - MSN
Is Alzamend Neuro Inc. stock attractive for passive investors2025 Earnings Impact & Daily Profit Focused Stock Screening - BỘ NỘI VỤ
Alzamend Neuro: Will Topline Data Spark Investor Interest? - RTTNews
Alzamend Neuro's AL001 formulation highlights its potential to treat disorders such a Alzheimer's - SelectScience
What margin trends mean for Alzamend Neuro Inc. stockWeekly Market Outlook & Verified Swing Trading Watchlists - newser.com
Why Alzamend Neuro Inc. stock could see breakout soonProduct Launch & High Return Trade Opportunity Guides - newser.com
Why Alzamend Neuro Inc. stock could benefit from AI revolutionTrade Risk Report & Daily Profit Maximizing Tips - newser.com
Can Alzamend Neuro Inc. stock sustain revenue growthMarket Risk Analysis & Pattern Based Trade Signal System - newser.com
Will Alzamend Neuro Inc. stock rally after Fed decisionsJuly 2025 Closing Moves & Safe Swing Trade Setup Alerts - newser.com
Will Alzamend Neuro Inc. stock reach all time highs in 2025Exit Point & Daily Technical Forecast Reports - newser.com
Alzamend completes clinical portion of phase II trial for lithium therapy - Investing.com Nigeria
Published on: 2025-11-19 13:20:00 - newser.com
Alzamend Neuro announces passing of board member Andrew H. Woo By Investing.com - Investing.com Australia
Comparing Alzamend Neuro Inc. in custom built stock radarsWeekly Risk Summary & Weekly Momentum Picks - newser.com
Alzamend Neuro announces completion of clinical portion of phase II clinical trial of AL001 "lithium in brain" study conducted at Massachusetts General Hospital - MarketScreener
Alzamend rises after completing mid-stage brain lithium study - TradingView
Alzamend Neuro (Nasdaq: ALZN) completes AL001 Phase II trial; 2026 lithium imaging data - Stock Titan
EXCLUSIVE: Alzamend Wraps Clinical Phase Of AL001 Study In Healthy Participants - Benzinga
Multi asset correlation models including Alzamend Neuro Inc.Oil Prices & Fast Exit/Entry Strategy Plans - newser.com
Is Alzamend Neuro Inc. stock cheap compared to fundamentalsWeekly Trend Summary & Safe Capital Growth Plans - newser.com
Alzamend Neuro Inc Azioni (ALZN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.52%
0.07%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):